MRC Developmental Pathway Funding Scheme (DPFS)

The Medical Research Council Developmental Pathway Funding Scheme is the MRC’s invite-only translational route for academically led projects that can move a health idea toward use. It sits under UK Research and Innovation and focuses on prevention, diagnosis, prognosis, and treatment of serious health needs. The current Stage 2 call follows successful Stage 1 assessment. The scheme supports novel therapeutics, vaccines, biologics, advanced therapeutics, regenerative medicine, repurposing, medical devices, digital healthcare, diagnostics, imaging, and surgical or behavioural interventions. The current fund is GBP 26 million, with support at 80% of full economic cost and 100% only for permitted exceptions. The Stage 2 window opens 10 December 2025 and closes 8 July 2026, with a decision meeting on 14 to 15 October 2026. International researchers may join as project co-leads. DPFS is not for basic research without a development plan, late-phase clinical trials, or broad population health solutions. It fits teams that can show a credible translational route, a focused product or intervention, and enough development maturity to justify an invited second-stage application. The route is strongest when the proposal is tightly scoped, clinically relevant, and ready for expert review at both stages.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.